BioAxone Therapeutic

BioAxone is dedicated to deepening the understanding of axonal regeneration and neuronal signaling pathways to transform the lives of patients with neurotrophic tumors or neurovascular diseases. Leveraging 20 years of pioneering research in axonal regeneration and diseases involving Rho/ROCK signaling, BioAxone has a clinical-stage drug (BA-210) and a preclinical program for axonal regeneration (BA-434) for the treatment of spinal cord injuries. BA-1049 is an orally administered ROCK2 inhibitor used to restore endothelial cell barrier function in hemangiomas and cerebral aneurysms.